MedTrace Logo

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

NCT06214052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.

Conditions

  • HIV Infections

Interventions

DRUG

VH4524184

VH4524184 was administered as tablets orally at Day 1.

DRUG

Matching Placebo

VH4524184 Matching Placebo was administered as tablets orally at Day 1.

DRUG

Antiretroviral therapy

Antiretroviral therapy was administered as available and as per investigator's recommendation.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-07
Primary Completion
2024-06-12
Completion
2024-06-12
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06214052 on ClinicalTrials.gov